To study the effect of Unani drug in the treatment of patients with Chronic obstructive pulmonary disease.

A clinical study on the effects of a Unani compound formulation on spirometry parameter in chronic obstructive pulmonary disease patients.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/02/012180

Enrollment

Registered

2018-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Obstructive Pulmonary Disease (COPD) Health Condition 2: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: Lauq-e-katan (a Unani formulation): The patients were advice to take 10 gm of test drug three times a day i.e. (total dose 30 Gms / day) before meals.for 6 wks Control Intervention1: Th

Eligibility

Inclusion criteria

Inclusion criteria: Known Moderate cases of COPD based on Gold Criteria defined by WHO. Patients who are willing to participate

Exclusion criteria

Exclusion criteria: Patients aged less than 18 years Patients having acute exacerbation of breathlessness Patients having severe or very severe COPD. patients taking Î²-blockers/ACE inhibitors Patients suffering from Diabetes Mellitus, Hepatic Failure, Renal Failure, Congestive Heart Failure. Pregnant and lactating mothers.

Design outcomes

Primary

Measure	Time frame
Improvement in Spirometric Parameters (FEV1, FEV1/FVC ) Timepoint: after 6 wks of the treatment	—

Secondary

Measure	Time frame
Improvement in MRC-D ScaleTimepoint: after 6 wks of the treatment	—

Countries

India

Contacts

Public ContactDr Asim Ali Khan

Faculty of Medicine (U), Jamia Hamdard, New Delhi

jabeendr@gmail.com9899315252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026